serpin family B member 7Genealiases: MEGSIN · PPKN · TP55
Q-omics provides the consensus-scored SERPINB7 profile across patient tissues and cancer cell-line models. SERPINB7 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, SERPINB7 is differentially expressed in 9, with the highest sampling consensus in LUSC. Additionally, SERPINB7 protein abundance shows 21,298 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight BRCA, LUSC, and LUAD as cancer lineages where SERPINB7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SERPINB7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SERPINB7 survival associations across molecular data types. SERPINB7 RNA expression shows survival associations in the most cancer types (19), followed by mutation status (8) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SERPINB7 RNA expression–survival associations across cancer types. High SERPINB7 expression shows unfavorable associations in BRCA, LIHC, BLCA, PAAD and STAD, but favorable associations in COAD. The BRCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BRCA as the clearest survival context for SERPINB7 RNA expression.
This table summarizes SERPINB7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 6. The strongest signals are observed in LUSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for SERPINB7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SERPINB7 shows lower tumor expression in KIRC and higher tumor expression in LUSC, COAD, BRCA, BLCA and LUAD. The LUSC box plot shows higher SERPINB7 RNA expression in tumor versus normal tissue (log2 FC = +2.802, t-test p < 0.001).
This table shows molecular features associated with SERPINB7 in patient tissues and cancer cell lines. In patient samples, SERPINB7 shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, SERPINB7 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in CNS and BONE.
